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Objectives The purpose of this study was to determine the possible benefit of dual antiplatelet therapy in patients with prior
myocardial infarction (MI), ischemic stroke, or symptomatic peripheral arterial disease (PAD).
Background Dual antiplatelet therapy with clopidogrel plus aspirin has been validated in the settings of acute coronary syn-
dromes and coronary stenting. The value of this combination was recently evaluated in the CHARISMA (Clopi-
dogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance) trial, where no
statistically significant benefit was found in the overall broad population of stable patients studied.
Methods We identified the subgroup in the CHARISMA trial who were enrolled with documented prior MI, ischemic stroke,
or symptomatic PAD.
Results A total of 9,478 patients met the inclusion criteria for this analysis. The median duration of follow-up was 27.6
months. The rate of cardiovascular death, MI, or stroke was significantly lower in the clopidogrel plus aspirin arm
than in the placebo plus aspirin arm: 7.3% versus 8.8% (hazard ratio [HR] 0.83, 95% confidence interval [CI]
0.72 to 0.96, p  0.01). Additionally, hospitalizations for ischemia were significantly decreased, 11.4% versus
13.2% (HR 0.86, 95% CI 0.76 to 0.96, p  0.008). There was no significant difference in the rate of severe
bleeding: 1.7% versus 1.5% (HR 1.12, 95% CI 0.81 to 1.53, p  0.50); moderate bleeding was significantly in-
creased: 2.0% versus 1.3% (HR 1.60, 95% CI 1.16 to 2.20, p  0.004).
Conclusions In this analysis of the CHARISMA trial, the large number of patients with documented prior MI, ischemic stroke,
or symptomatic PAD appeared to derive significant benefit from dual antiplatelet therapy with clopidogrel plus
aspirin. Such patients may benefit from intensification of antithrombotic therapy beyond aspirin alone, a concept
that future trials will need to validate. (Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization,
Management, and Avoidance [CHARISMA]; http://clinicaltrials.gov/ct/show/NCT00050817?order1;
NCT00050817) (J Am Coll Cardiol 2007;49:1982–8) © 2007 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.03.025
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May 15, 2007:1982–8 Patients With Prior MI, Stroke, or PAD in the CHARISMA Trialual antiplatelet therapy with aspirin plus clopidogrel has been
tudied extensively and found to be superior to aspirin alone in
atients with acute coronary syndromes and after stent implan-
ation for up to a year of therapy (1–3). The combination was
ost recently evaluated in the CHARISMA (Clopidogrel for
igh Atherothrombotic Risk and Ischemic Stabilization,
anagement, and Avoidance) trial (4). The overall trial found
nonsignificant 7.1% relative risk reduction in the primary
fficacy end point of cardiovascular death, myocardial infarc-
ion (MI), or stroke over a median of 28 months and a similar
ut statistically significant 7.7% relative risk reduction in the
econdary efficacy end point, which included hospitalization
or ischemia or revascularization (4).
The CHARISMA study enrolled a stable population
ith either established atherothrombotic disease or multiple
isk factors for atherothrombotic events (5). In a prespeci-
ed analysis of the CHARISMA trial, the 12,153 patients
nrolled with established disease (documented cardiovascu-
ar, cerebrovascular, or peripheral arterial disease [PAD])
eemed to derive a significant benefit from combination
herapy, while the 3,284 patients without documented
isease but with multiple risk factors did not derive any
enefit (4).
The CAPRIE (Clopidogrel Versus Aspirin in Patients at
isk of Ischemic Events) trial had previously demonstrated
n a stable secondary prevention population that clopidogrel
onotherapy was superior to aspirin monotherapy for
educing the composite of vascular death, MI, or stroke, as
ell as hospitalization for ischemic events (6,7), and that
his benefit was further amplified in higher-risk subgroups
rom the CAPRIE trial such as those with prior ischemic
vents (8). We hypothesized that if the CHARISMA trial
ad examined only a “CAPRIE-like” high-risk secondary
revention population instead of a broader and overall
rom the *Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland,
hio; †Clinical Trials and Evaluation Unit, Royal Brompton Hospital, London,
nited Kingdom; ‡Department of Neurology, University of Heidelberg, Heidelberg,
ermany; §Geisinger Center for Health Research, Danville, Pennsylvania; New
ork University School of Medicine, New York, New York; ¶Division of Cardiology,
aleida Healthcare, Buffalo, New York; #Department of Internal Medicine, Hopital
itie-Salpetriere, Paris, France; **Division of Cardiology, Sunnybrook and Women’s
ollege Health Science Centre, Toronto, Canada; ††Division of Cardiovascular
edicine, Brigham and Women’s Hospital and Harvard Medical School, Boston,
assachusetts; ‡‡Department of Neurology, Rhode Island Hospital and Brown
niversity, Providence, Rhode Island; §§Department of Cardiology, Kerckhoff-
linik Center, Bad Nauheim, Germany; Department of Neurology, Royal Perth
ospital and School of Medicine and Pharmacology, The University of Western
ustralia, Perth, Australia; ¶¶Department of Neurology, University of California San
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ochester School of Medicine, Rochester, New York; §§§Service de Cardiologie,
ôpital Bichat, Paris, France; Division of Cardiology, University of Kentucky,
exington, Kentucky; ¶¶¶SUNY Downstate Medical Center College of Medicine,
rooklyn, New York; ###Case Western Reserve University, Cleveland, Ohio; and
***University and Royal Infirmary of Edinburgh, Edinburgh, United Kingdom. The
HARISMA study was funded by Sanofi-Aventis and Bristol-Myers Squibb. Please
ee the Appendix for complete author disclosure information.i
Manuscript received December 4, 2006; revised manuscript received March 16,
007, accepted March 20, 2007.ower-risk population, as was ac-
ually done, greater benefit of
ual antiplatelet therapy over as-
irin might have been evident.
ethods
he design of the CHARISMA
rial has been published previ-
usly (9). Briefly, patients with
ocumented coronary artery disease, cerebrovascular dis-
ase, or PAD, or with multiple risk factors for atherothrom-
osis were enrolled and randomized in double-blind fashion
o clopidogrel plus aspirin or placebo plus aspirin and
ollowed for a median of 28 months. Patients were excluded
f they had indications for open-label clopidogrel use or
ere at high risk of bleeding.
For the purposes of this post hoc analysis, patients were
dentified as “CAPRIE-like” if they were enrolled with a
ocumented prior MI, documented prior ischemic stroke,
r symptomatic PAD. Symptomatic PAD was defined as
ither current intermittent claudication with an ankle bra-
hial index 0.85 or a history of intermittent claudication
ith a previous related intervention (amputation, peripheral
ypass surgery, endovascular procedure). In the CAPRIE
rial, the time limit for entry for stroke was 1 week to 6
onths after the event and 35 days for MI; unlike the
nclusion criteria in the CAPRIE trial, for the current
nalysis, no time limit was set with respect to the occurrence
f the prior ischemic event.
The primary efficacy end point was cardiovascular death
including hemorrhagic death), MI, or stroke (from any
ause). The primary safety end point was severe bleeding as
efined by the GUSTO (Global Utilization of Streptoki-
ase and t-PA for Occluded Coronary Arteries) criteria,
hich includes fatal bleeding, primary intracranial hemor-
hage, or bleeding that causes hemodynamic compromise
nd requires blood or fluid replacement, inotropic support,
r surgical intervention (10). These events were validated by
he Cleveland Clinic Clinical Events Adjudication Com-
ittee. The secondary efficacy end point consisted of
ardiovascular death, MI, stroke, or rehospitalization for
nstable angina, transient ischemic attack, or a revascular-
zation procedure (coronary, cerebral, or peripheral). Mod-
rate bleeding as determined by the GUSTO criteria was
he secondary safety end point; this end point captures
leeding that leads to transfusion but that does not lead to
emodynamic compromise that requires intervention (10).
tatistical analysis. The efficacy of clopidogrel plus aspirin
ersus placebo plus aspirin was assessed using a 2-sided
og-rank test. Treatment effect, as measured by the hazard ratio
HR) (relative risk) and its associated 95% confidence interval
CI), was estimated using Cox’s proportional hazards model.
umulative Kaplan-Meier estimates of the event rates were
lso calculated. Statistical comparisons of the safety event rates
Abbreviations
and Acronyms
CI  confidence interval
HR  hazard ratio
MI  myocardial infarction
PAD  peripheral arterial
diseasen the 2 treatment groups were performed using a 2-sided
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Patients With Prior MI, Stroke, or PAD in the CHARISMA Trial May 15, 2007:1982–8og-rank test. No adjustments for multiple comparisons were
ade. Multivariate analysis incorporating baseline demograph-
cs, concomitant medications, and time from enrolling isch-
mic event was performed to examine any independent effect
f the randomized treatment. The instantaneous hazard func-
ions of primary efficacy and safety end points were estimated
y the life-table method as the first 30 days, 30 to 90 days, 90
o 180 days, and then every 180 days. All analyses were
erformed using SAS version 8.2 (SAS Institute Inc., Cary,
orth Carolina).
esults
total of 9,478 patients fulfilled the “CAPRIE-like” criteria
or this analysis. A total of 3,846 patients had prior MI, with
median time from the qualifying event to randomization of
3.6 months; 3,245 patients had prior stroke, with a median
ime from event of 3.5 months; 2,838 patients had symptom-
tic PAD, with a median time from diagnosis of 23.6 months.
ote that 443 (4.7%) patients fell into multiple categories
ecause they actually had more than 1 prior event or disease
Baseline Characteristics
Table 1 Baseline Characteristics
Characteristic
Demographics
Age (yrs), median (Q1, Q3)
Female patients, n (%)
Ethnicity, n (%)
Caucasian
Hispanic
Asian
Black
Other
Inclusion group, n (%)
Prior myocardial infarction
Prior ischemic stroke
Symptomatic PAD
Selected clinical characteristics, n (%)
Smoking status
Current
Former
Hypertension
Hypercholesterolemia
Congestive heart failure
Prior myocardial infarction
Atrial fibrillation
Prior stroke
Transient ischemic attack
Diabetes
PAD
Percutaneous coronary intervention
Coronary artery bypass graft surgery
Carotid endarterectomy
Peripheral angioplasty or bypass
Diabetic nephropathy
PAD  peripheral arterial disease.ocation. The baseline characteristics of these patients in the 2 pandomized arms were well matched, with no significant
ifferences (Table 1). Concomitant medication use was also
imilar in the 2 arms of the study except nitrate use, which was
5.8% in the aspirin plus placebo arm and 23.5% in the aspirin
lus clopidogrel arm (p  0.008) (Table 2).
The overall rate of cardiovascular death, MI, or stroke in
his cohort was 8.8% in the placebo plus aspirin arm and
.3% in the clopidogrel plus aspirin arm (HR 0.83, 95% CI
.72 to 0.96, p 0.01) (Fig. 1). The interaction term for the
enefit in this subgroup was 0.005. Significant benefit was
lso evident for the secondary efficacy end point incorporat-
ng hospitalization for ischemic events (Table 3). Patients
ith prior MI or prior stroke appeared to have a similar
elative risk reduction as those with symptomatic PAD,
lthough the risk reduction in the PAD subgroup did not
each statistical significance (Fig. 2). Overall, those patients
ith disease in multiple (that is, 2 or 3) vascular locations
prior events such as MI or stroke or established PAD) had
14.7% rate of cardiovascular death, MI, or stroke versus a
.7% rate in those having only 1 vascular location (either
idogrel  Aspirin
(n  4,735)
Placebo  Aspirin
(n  4,743)
64 (56, 71) 64 (56, 71)
,292 (27.3) 1,275 (26.9)
,859 (81.5) 3,851 (81.2)
454 (9.6) 481 (10.1)
226 (4.8) 222 (4.7)
141 (3.0) 137 (2.9)
55 (1.2) 52 (1.1)
,903 (40.2) 1,943 (41.0)
,634 (34.5) 1,611 (34.0)
,418 (29.9) 1,420 (29.9)
,024 (21.6) 1,055 (22.2)
,434 (51.4) 2,435 (51.3)
,236 (68.3) 3,317 (69.9)
,307 (69.8) 3,343 (70.5)
298 (6.3) 308 (6.5)
,193 (46.3) 2,248 (47.4)
172 (3.6) 160 (3.4)
,764 (37.3) 1,726 (36.4)
326 (6.9) 300 (6.3)
,457 (30.8) 1,484 (31.3)
,529 (32.3) 1,530 (32.3)
,209 (25.5) 1,239 (26.1)
809 (17.1) 829 (17.5)
257 (5.4) 235 (5.0)
829 (17.5) 812 (17.1)
195 (4.1) 211 (4.4)Clop
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ultiple vascular locations had an 18.5% rate of cardiovas-
ular death, MI, or stroke in the placebo plus aspirin arm
ersus a 10.6% rate with clopidogrel plus aspirin (HR 0.55,
5% CI 0.33 to 0.91, p  0.018).
In the 2,675 patients who were excluded from the original
HARISMA group of “established cardiovascular disease” to
Concomitant Medications
Table 2 Concomitant Medications
Medication
Aspirin
Diuretics
Nitrates
Calcium antagonists
Beta-blockers
Angiotensin II receptor blockers
Ramipril
Other angiotensin-converting enzyme inhibitors
Other antihypertensives
Statins
Atorvastatin
Simvastatin
Pravastatin
Fluvastatin
Lovastatin
Other statins
Other lipid-lowering agents
Fibrates
Binding resins
Nicotinic acid
Antidiabetic medications
Insulin
Thiazolidinediones
Other oral hypoglycemics
Values are expressed as n (%).
Figure 1 Kaplan-Meier Curves for Cardiovascular Death, MI, or
Stroke for Clopidogrel  ASA Versus Placebo  ASA
Kaplan-Meier event curves for the primary end point of cardiovascular death,
myocardial infarction (MI), or stroke. ASA  aspirin; CI  confidence interval;
RRR  relative risk reduction.perive the current study population, there were patients with
ngina and documented multivessel coronary artery disease, a
istory of percutaneous coronary intervention, a history of
oronary artery bypass surgery, and those with transient isch-
mic attacks. In this excluded cohort of patients with stable
ardiovascular disease without documented thrombotic events,
here was no benefit of clopidogrel plus aspirin versus placebo
lus aspirin; the rate of cardiovascular death, MI, or stroke was
.5% versus 4.7% (HR 1.16, 95% CI 0.83 to 1.63, p  0.38);
or the end point of cardiovascular death, MI, stroke, or
ospitalization for ischemic events, the rate was 17.7% versus
7.1% (HR 1.04, 95% CI 0.87 to 1.24, p  0.69). Figure 3
hows the primary efficacy end point for the patients enrolled
ith MI (Fig. 3A) versus those enrolled with coronary artery
isease other than MI (Fig. 3B).
For the “CAPRIE-like” cohort, the individual components
f the composite end point as well as additional secondary end
oints and bleeding end points are listed in Table 3. There was
o significant difference in severe bleeding, though moderate
leeding was significantly increased with dual antiplatelet
herapy: 2.0% versus 1.3% (HR 1.60, 95% CI 1.16 to 2.20,
 0.004). In an attempt to define net clinical benefit, the rate
f cardiovascular death, MI, stroke, or severe GUSTO bleed-
ng was examined and found to be 9.4% in the placebo plus
spirin arm versus 8.3% in the clopidogrel plus aspirin arm
HR 0.87, 95% CI 0.76 to 1.00, p  0.051).
Multivariate analysis revealed treatment with clopidogrel
lopidogrel  Aspirin
(n  4,735)
Placebo  Aspirin
(n  4,743)
4,720 (99.7) 4,732 (99.8)
2,102 (44.4) 2,086 (44.0)
1,112 (23.5) 1,225 (25.8)
1,601 (33.8) 1,647 (34.7)
2,639 (55.7) 2,696 (56.8)
1,035 (21.9) 1,048 (22.1)
872 (18.4) 893 (18.8)
2,129 (45.0) 2,161 (45.6)
496 (10.5) 528 (11.1)
3,651 (77.1) 3,646 (76.9)
1,651 (34.9) 1,663 (35.1)
1,686 (35.6) 1,682 (35.5)
622 (13.1) 607 (12.8)
139 (2.9) 139 (2.9)
156 (3.3) 156 (3.3)
258 (5.4) 239 (5.0)
580 (12.2) 543 (11.4)
337 (7.1) 291 (6.1)
171 (3.6) 171 (3.6)
156 (3.3) 140 (3.0)
1,445 (30.5) 1,490 (31.4)
592 (12.5) 582 (12.3)
214 (4.5) 230 (4.8)
1,171 (24.7) 1,205 (25.4)Clus aspirin to be an independent predictor of freedom from
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Patients With Prior MI, Stroke, or PAD in the CHARISMA Trial May 15, 2007:1982–8ardiovascular death, MI, or stroke; the HR for cardiovascular
eath, MI, or stroke in patients randomized to clopidogrel plus
spirin instead of placebo plus aspirin was 0.84 (95% CI 0.73
o 0.97, p 0.019). The effect of time from the ischemic event
r diagnosis to randomization was included in the model and
here was no significant effect of time with regard to outcome,
lthough such testing may have been underpowered. There-
ore, the primary end points at various times from the ischemic
vent are presented (Table 4); these data are also presented as
n instantaneous hazard function from the time of random-
zation (Fig. 4). Besides randomization to clopidogrel, other
redictors of decreased risk of cardiovascular death, MI, or
troke were female gender, concomitant statin use, and con-
omitant use of other lipid-lowering therapies. Significant
redictors of cardiovascular death, MI, or stroke were increas-
ng age, history of congestive heart failure, history of stroke,
rimary and Secondary Efficacy and Bleeding End Points
Table 3 Primary and Secondary Efficacy and Bleeding End Poin
End Point
Clopidogrel  Aspirin
(n  4,735)
Efficacy end points
Primary efficacy 347 (7.3)
All-cause mortality 235 (5.0)
Cardiovascular mortality 142 (3.0)
Myocardial infarction* 117 (2.5)
Ischemic stroke* 126 (2.7)
Stroke* 144 (3.0)
Secondary efficacy 831 (17.6)
Hospitalization† 542 (11.4)
Safety end points
Severe bleeding 79 (1.7)
Fatal bleeding 15 (0.3)
Primary intracranial hemorrhage 17 (0.4)
Moderate bleeding 97 (2.0)
Fatal plus nonfatal events. †For unstable angina, transient ischemic attack, or revascularization
CI  confidence interval; HR  hazard ratio.
Figure 2 Hazard Ratio for the Primary End Point in Patients En
Hazard ratio (HR) and 95% CI for the composite of cardiovascular death, MI, or str
plus aspirin that were enrolled with a prior MI, prior ischemic stroke (IS), or symptiastolic blood pressure 80 mm Hg, increasing neutrophil
ount, concomitant anticoagulants, concomitant antidiabetic
edications, and current smoking.
iscussion
en years ago, the CAPRIE trial demonstrated the supe-
iority of clopidogrel monotherapy over aspirin mono-
herapy in patients with recent MI, stroke, or symptomatic
AD over the 36-month study duration (6). The combina-
ion of clopidogrel plus aspirin was then validated as a
herapeutic strategy in the CURE (Clopidogrel in Unstable
ngina to Prevent Recurrent Ischemic Events) and
REDO (Clopidogrel to Reduce Events During Observa-
ion) trials of acute coronary syndromes and stenting,
espectively (2,3). The CHARISMA trial was an ambitious
Placebo  Aspirin
(n  4,743) HR (95% CI) p Value
416 (8.8) 0.829 (0.719–0.956) 0.010
257 (5.4) 0.914 (0.765–1.090) 0.316
163 (3.4) 0.870 (0.695–1.090) 0.224
145 (3.1) 0.805 (0.631–1.027) 0.080
152 (3.2) 0.828 (0.654–1.048) 0.115
179 (3.8) 0.802 (0.644–0.998) 0.048
938 (19.8) 0.872 (0.794–0.958) 0.004
626 (13.2) 0.855 (0.762–0.960) 0.008
71 (1.5) 1.114 (0.808–1.535) 0.509
11 (0.2) 1.362 (0.626–2.966) 0.434
20 (0.4) 0.849 (0.445–1.621) 0.619
61 (1.3) 1.597 (1.159–2.200) 0.004
With Prior MI, Stroke, or PAD
r patients randomized to placebo plus aspirin versus clopidogrel
 peripheral arterial disease (PAD). Abbreviations as in Figure 1.tsrolled
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May 15, 2007:1982–8 Patients With Prior MI, Stroke, or PAD in the CHARISMA Trialttempt to examine dual antiplatelet therapy in a much
roader population than the CAPRIE trial, with the addi-
ional inclusion of lower-risk secondary prevention as well as
rimary prevention types of patients (4). The CHARISMA
rial overall did not show a statistically significant benefit in
he primary efficacy end point, although it did show a
ignificant benefit in the secondary efficacy end point. The
urrent post hoc subgroup analysis of patients with prior
I, stroke, or symptomatic PAD from the CHARISMA
rial shows a statistically significant 1.5% absolute risk
Figure 3 Kaplan-Meier Curves for the Primary End Point in
Patients With CAD Either With or Without Prior MI
(A) Kaplan-Meier curves for the primary end point of cardiovascular death, MI,
or stroke in patients enrolled with prior MI. (B) Kaplan-Meier curves for the pri-
mary end point in patients enrolled with coronary artery disease without prior
MI. Abbreviations as in Figures 1 and 2.
Rates of Cardiovascular Death, Myocardial Infarat Different Time Intervals From the Ischemic E
Table 4 Rates of Cardiovascular Death, Myoat Different Time Intervals From the
Time of Ischemic Event Prior
to Randomization Clopidogrel  As
Within 30 days 8.2% (86/1,05
Between 30 to 300 days 6.7% (68/1,01
Between 300 days to 30 months 6.8% (68/997)
More than 30 months 6.6% (71/1,07Abbreviations as in Table 3.eduction in the composite of cardiovascular death, MI, or
troke over a median of 27.6 months. This compares with a
% absolute risk reduction in the same end point in the
URE trial over a median of 9 months.
Thus, there appears to be a gradient of benefit for dual
ntiplatelet therapy depending on the risk of thrombotic
vents of the patient. A reduction in all-cause mortality with
hort-term clopidogrel given in addition to aspirin was
bserved in the COMMIT (Clopidogrel and Metoprolol in
yocardial Infarction) trial (11), with significant 2% to 3%
bsolute risk reductions in composite ischemic end points
een in the CURE and CREDO trials (20 to 30 ischemic
vents prevented per 1,000 patients treated for about 1
ear). In comparison, the CAPRIE-like cohort from the
HARISMA trial shows a more modest degree of benefit,
ith 14.4 episodes of cardiovascular death, MI, or stroke
verted over the course of an average of 27.6 months per
, or Stroketo Randomization
ial Infarction, or Stroke
emic Event to Randomization
Placebo  Aspirin HR (95% CI)
10.5% (109/1,041) 0.773 (0.583–1.025)
8.0% (83/1,036) 0.831 (0.603–1.146)
8.0% (81/1,018) 0.848 (0.614–1.171)
7.2% (74/1,034) 0.918 (0.663–1.271)
Figure 4 Instantaneous Hazard for Cardiovascular Death,
MI, or Stroke or for Severe or Moderate Bleeding
(A) Instantaneous hazard for cardiovascular death, MI, or stroke. (B) Instanta-
neous hazard for severe or moderate bleeding. Abbreviations as in Figure 1.ctionvent
card
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Patients With Prior MI, Stroke, or PAD in the CHARISMA Trial May 15, 2007:1982–8,000 patients treated, at a cost of 1.7 severe bleeds. Of note,
here was no statistically significant increase in severe
leeding, including fatal bleeding or intracranial hemor-
hage. Additionally, during the median of 27.6 months,
7.5 hospitalizations for ischemic events (unstable angina,
ransient ischemic attack, worsening PAD) or revascular-
zation were prevented at the cost of an additional 7.6
oderate bleeds (essentially, transfusions).
The benefit on ischemic outcomes started soon after
andomization with increasing separation of the event
urves as duration of therapy increased. Examination of the
ctual event rates showed that the largest absolute benefit
ppeared to be in patients whose ischemic event was within
he prior month, with a lower absolute benefit seen between
0 days and 30 months, with further attenuation of observed
enefit beyond 30 months; it is biologically plausible that
he greatest degree of benefit would be in those whose
schemic event was most recent, although this analysis was
nderpowered to detect any definite time-related effect.
everal patterns emerge upon examination of this data set.
he benefit in preventing ischemic events is greatest early
fter randomization. The benefit in preventing ischemic
vents is less in patients who are further removed from the
ast previous ischemic event at the time of randomization.
he bleeding excess is also “front-loaded,” with more
leeding seen with dual antiplatelet therapy compared with
spirin plus placebo in the first few months of therapy and
ittle difference afterward. All of these patterns are not
tatistically significant per se, as the study lacks power to
ake a definitive statement regarding these observations.
Based on the findings in the subgroup of 2,675 patients who
ere excluded from the original CHARISMA group of
established cardiovascular disease” to derive the current study
opulation, it appears that patients with angina and docu-
ented multivessel coronary artery disease, a history of remote
ercutaneous coronary intervention, a history of coronary artery
ypass surgery, or those with transient ischemic attacks may
ot benefit from dual antiplatelet therapy. Thus, it seems that
t is those patients who have had plaque rupture and throm-
osis in the past that are most likely to derive benefit from an
xtended duration of dual antiplatelet therapy.
There are evident limitations to this analysis. As a post
oc subgroup analysis, it can only be considered hypothesis
enerating. Even large subgroup analyses may be misleading
nd provide spurious results. Nevertheless, with over 9,000
atients, it is a large subgroup that consists of a logical
ohort to analyze given the initial findings of the CAPRIE
rial. Furthermore, in this subgroup, the baseline character-
stics of the clopidogrel plus aspirin and placebo plus aspirin
roups were well matched without any significant differ-
nces, and the results persisted after multivariable analysis.
In conclusion, patients with documented prior MI,
troke, or symptomatic PAD in the CHARISMA trial
ppeared to have significant benefit from a reduction in pschemic events from dual antiplatelet therapy with clopi-
ogrel plus aspirin versus placebo plus aspirin, which was
omewhat offset by an increase in moderate, although not
evere, bleeding. Such patients may benefit from intensifi-
ation of antithrombotic therapy beyond aspirin alone, a
oncept that future trials will need to validate.
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